Suresh Ramalingam, MD
Physician Scientist

"The results of our study usher in a new treatment paradigm for the treatment of patients with an EGFR-mutated lung cancer."

Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation experienced substantial improvement in outcomes when treated with the drug osimertinib compared with those who receive standard of care treatment. The findings, released November 18, 2017 in the New England Journal of Medicine on-line, are based on results of the FLAURA study led by Suresh S. Ramalingam, MD, from Winship Cancer Institute of Emory University.

"These results usher in a new treatment paradigm for the treatment of patients with an EGFR-mutated lung cancer," says Ramalingam, Winship deputy director and the Roberto C. Goizueta Distinguished Chair for Cancer Research in the Emory School of Medicine. "The use of osimertinib resulted in a 54% reduction in the risk of progression of the disease or death as compared to the present standard treatment approach."



Cascade Link   TOP